HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Global Panel Focuses On Developing Countries’ Reg Systems

This article was originally published in The Tan Sheet

Executive Summary

An FDA Science Board subcommittee will assess safety awareness in countries exporting food and medical products to the U.S., and identifies promising approaches to strengthening regulatory systems in those countries, says Chairman Jeff Bender.

You may also be interested in...



Congress Instructs FDA On Nanotech Work, But Mum On Regulations

The recently passed user fee reauthorization includes a provision that directs FDA to evaluate nano-engineered products’ potential benefits and safety. Friends of the Earth says nanotech products are available “prematurely … without having enough safety data.”

IOM Pushes For FDA Collaboration With Foreign Regulators

In a report on how FDA, industry and other stakeholders can strengthen food and drug regulatory systems abroad, the Institute of Medicine recommends the agency provide incentives for foreign regulators to meet U.S. standards and facilitate training and for the government to help hold importers liable.

Louis Jacques On Coverage, Evidence And IDEs

Former CMS coverage director Louis Jacques talks about the strong future ahead he envisions for the Medicare coverage-with-evidence-development program and new coverage policies that will be implemented for investigational device exemption trials.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS124794

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel